Early lung cancer responses push ACR-2316 into a broader randomized trial

Acrivon Therapeutics is putting one of its most important platform claims into a larger clinical test after advancing ACR-2316 into randomized dose expansion across six solid-tumor populations. The decision turns durable responses from a very small group of heavily pretreated patients into a broader evaluation of whether the company’s AP3 precision-oncology platform can identify cancers that are vulnerable to dual WEE1 and PKMYT1 inhibition. Two oral dose levels will be compared under principles promoted by the United States Food and Drug Administration’s Project Optimus initiative. With Acrivon Therapeutics valued at approximately $62 million and its latest reported cash runway extending into the third quarter of 2027, the expansion is also an important test of the company’s ability to create clinical value before it requires additional financing.

ACR-2316 will be tested at 120 milligrams and 160 milligrams once daily for three consecutive days followed by four days without treatment. The randomized expansion will include small cell lung cancer, squamous non-small cell lung cancer, lung adenocarcinoma, endometrial cancer, cervical cancer and cancer of the esophagogastric junction. Patients will be separated into lung and non-lung groups before being assigned equally to the two doses.

The advancement follows preliminary results from 35 participants treated across six dose levels. Among seven evaluable patients with three different forms of lung cancer, two achieved partial responses, four had stable disease and one experienced progressive disease, producing an 86% disease control rate. Three heavily pretreated lung cancer patients remained on ACR-2316 for more than one year.

Those outcomes justify continued development, but they do not establish a reliable response rate. Every patient carries substantial weight in a seven-person dataset, and the study does not include a control group showing how patients might have performed without ACR-2316. The randomized expansion must now determine whether the early activity is reproducible, whether it is concentrated in specific cancer types and which dose offers the strongest balance between antitumor activity and tolerability.

Randomized dose expansion will test whether the 86% disease control result can scale

Acrivon Therapeutics selected the 120-milligram and 160-milligram weekly regimens after evaluating doses ranging from 30 milligrams to 240 milligrams. The company also explored a less frequent schedule involving three treatment days followed by 11 days without treatment, but that approach was deprioritized in favor of the weekly regimen.

The decision not to simply carry the highest tested dose into expansion reflects a wider change in oncology drug development. The United States Food and Drug Administration’s Project Optimus initiative encourages companies to evaluate multiple doses and select the regimen that maximizes efficacy, safety and tolerability rather than assuming that the maximum tolerated dose is automatically the best commercial dose. The regulator has warned that poorly characterized regimens can add toxicity without increasing efficacy, cause frequent dose reductions and force patients to discontinue medicines that might otherwise provide continuing benefit.

For ACR-2316, the randomized comparison could determine whether 120 milligrams produces sufficient target activity with fewer blood-related adverse events or whether 160 milligrams provides enough additional tumor control to justify the higher exposure. The selected dose will influence future trial design, manufacturing forecasts and the commercial profile of the drug.

The initial tolerability findings support further study. Acrivon Therapeutics reported no Grade 4 or higher treatment-related adverse events with the two selected doses. Grade 3 treatment-related events were mainly temporary hematological abnormalities, particularly neutropenia, while the company highlighted the limited presence of non-hematological treatment-related toxicity.

Neutropenia can increase infection risk and may require treatment interruptions, dose reductions or supportive medicines. Its commercial importance will depend on how frequently it occurs, how long it lasts and whether the lower dose substantially reduces the problem without weakening efficacy.

The expansion also introduces greater biological complexity. Small cell lung cancer, squamous non-small cell lung cancer and lung adenocarcinoma are different diseases with distinct molecular characteristics and treatment standards. Combining them in an initial seven-patient analysis provides an early indication of activity, but each cancer type will eventually require enough patients to show whether ACR-2316 offers a dependable benefit.

ACR-2316’s dual-target design gives Acrivon differentiation but raises execution risk

WEE1 and PKMYT1 are kinases that help regulate when cells enter mitosis. Cancer cells carrying substantial DNA damage or replication stress may rely on these checkpoints to delay division, repair damage and survive. ACR-2316 is designed to inhibit both proteins while activating downstream cell-cycle regulators including CDK1, CDK2 and PLK1, pushing vulnerable tumor cells toward premature division and programmed cell death.

The dual-target approach is intended to overcome resistance mechanisms that can limit drugs focused on either WEE1 or PKMYT1 alone. Acrivon Therapeutics developed the molecule using AP3, its generative phosphoproteomics platform for measuring drug-regulated protein pathway activity within intact cells. The company uses those data to design compounds and identify tumor types that may be particularly sensitive to their pathway effects.

The expansion populations were chosen using biomarker features associated with cell-cycle vulnerability. These include loss or mutation of TP53 or FBXW7, overexpression or amplification of CCNE1 or CCNB1, and human papillomavirus positivity in cervical cancer.

This approach gives Acrivon Therapeutics a broader patient-selection strategy than one based on a single mutation. It could also make clinical validation harder. Pathway-based biomarkers must consistently distinguish responsive tumors from resistant ones across different cancer types, laboratories and tissue samples.

ACR-2316 is therefore testing more than a dual inhibitor. It is testing whether AP3 can produce commercially useful drug-design and patient-selection decisions. Repeatable responses across the prioritized tumor groups would strengthen the platform’s value and could support partnerships or additional internally developed programs. Inconsistent results would raise questions about whether promising pathway measurements can translate into predictable outcomes in patients.

Acrivon Therapeutics has also reported preclinical evidence that ACR-2316 may improve immune-mediated tumor killing and overcome resistance to PD-L1 checkpoint inhibition. That research may eventually support combination studies, but the immediate priority is establishing the drug’s single-agent activity and selecting a dose suitable for later development.

The company’s other major clinical asset, ACR-368, is being evaluated in a potentially registrational Phase 2b endometrial cancer study. ACR-368 has received Fast Track designation, while its accompanying OncoSignature assay has received Breakthrough Device designation. ACR-2316 gives the company a second opportunity to demonstrate that its precision-oncology strategy can create clinically differentiated medicines.

Cash runway and a low market value make upcoming data unusually important for shareholders

Acrivon Therapeutics reported $97.7 million in cash, cash equivalents and marketable securities at March 31, 2026. Together with $7.3 million raised through a subsequent equity financing, management expects the resources to fund operations into the third quarter of 2027 and through several anticipated clinical milestones.

The company recorded a first-quarter net loss of $19 million, including $15.2 million in research and development expenses. Those figures indicate that Acrivon Therapeutics has enough time to run the randomized expansion and obtain additional ACR-368 data, but its current resources are unlikely to fund every program through registration and commercialization. That conclusion is an inference based on the company’s spending, development stage and stated runway.

Future financing therefore remains a material risk. Strong ACR-2316 or ACR-368 results could improve the terms of an equity raise, attract a development partner or support a licensing agreement. Weak or inconclusive data could force the company to raise capital while its valuation remains depressed.

Acrivon Therapeutics shares traded at approximately $1.60 on August 5, up about 2.6% from the previous close. The stock moved between $1.57 and $1.64, while the company’s market capitalization stood near $62 million.

The modest gain suggests investors regarded the expansion as constructive but did not treat it as proof that ACR-2316 has been clinically validated. That interpretation is an inference from the trading pattern rather than a confirmed explanation from market participants.

The market capitalization is also below the company’s March-end cash and investment balance on a simple comparison. That does not mean the shares are automatically undervalued because the figure does not account for subsequent operating losses, liabilities or the cost of future trials. It does show that investors currently assign limited value to the pipeline after accounting for expected cash consumption.

ACR-2316 could change that perception if the expansion confirms durable responses across more patients and demonstrates that AP3 can select responsive populations. The strongest outcome would combine repeatable efficacy, manageable neutropenia and a clear distinction between the two doses.

The risk is that the 86% disease control rate proves to be a product of the tiny sample rather than a repeatable treatment effect. Acrivon Therapeutics has earned the right to run a larger test, but the randomized expansion must now convert a handful of encouraging cases into evidence capable of supporting a defined Phase 2 strategy.

Key takeaways on what ACR-2316 dose expansion means for Acrivon Therapeutics

• ACR-2316 has entered randomized dose expansion after showing tumor shrinkage and durable clinical benefit during Phase 1 dose escalation.
• Seven evaluable lung cancer patients produced an 86% disease control rate, including two partial responses and four cases of stable disease.
• Three heavily pretreated lung cancer patients remained on treatment for more than one year, providing the strongest evidence of durable activity.
• The dataset remains too small and uncontrolled to establish a dependable response rate or confirm superiority over existing treatment options.
• Acrivon Therapeutics will compare 120-milligram and 160-milligram doses using a three-days-on, four-days-off weekly schedule.
• The expansion covers six cancer populations selected using AP3-informed pathway and biomarker characteristics.
• Randomized dose testing follows Project Optimus principles and could identify a lower dose that preserves efficacy while reducing toxicity.
• Transient neutropenia remains the main reported treatment-related safety issue at the selected dose levels.
• Acrivon Therapeutics expects its latest reported cash resources to support operations into the third quarter of 2027, but additional financing is likely to be required for later-stage development.
• The company’s approximately $62 million market capitalization reflects cautious investor sentiment and leaves future valuation highly dependent on ACR-2316 and ACR-368 clinical data.